The association of vascular disorders with incident dementia in different age groups.

Abstract:

BACKGROUND:There is increasing evidence that dementia risk associated with vascular disorders is age dependent. Large population-based studies of incident dementia are necessary to further elucidate this effect. Therefore, the aim of the present study was to determine the association of vascular disorders with incident dementia in different age groups in a large primary care database. METHODS:We included 442,428 individuals without dementia aged ≥ 65 years from the longitudinal primary care Integrated Primary Care Information (IPCI) database. We determined in 6 age groups (from 65-70 to ≥ 90 years) the risk of hypertension, diabetes mellitus, dyslipidemia, stroke, myocardial infarction, heart failure, and atrial fibrillation for all-cause dementia using incidence rate ratios, Cox regression, and Fine and Gray regression models. RESULTS:The mean age at inclusion of the total study sample was 72.4 years, 45.7% of the participants were male, and median follow-up was 3.6 years. During 1.4 million person-years of follow-up, 13,511 individuals were diagnosed with dementia. The risk for dementia decreased with increasing age for all risk factors and was no longer significant in individuals aged ≥ 90 years. Adjusting for mortality as a competing risk did not change the results. CONCLUSIONS:We conclude that vascular disorders are no longer a risk factor for dementia at high age. Possible explanations include selective survival of individuals who are less susceptible to the negative consequences of vascular disorders and differences in follow-up time between individuals with and without a vascular disorder. Future research should focus on the identification of other risk factors than vascular disorders, for example, genetic or inflammatory processes, that can potentially explain the strong age-related increase in dementia risk.

journal_name

Alzheimers Res Ther

authors

Legdeur N,van der Lee SJ,de Wilde M,van der Lei J,Muller M,Maier AB,Visser PJ

doi

10.1186/s13195-019-0496-x

subject

Has Abstract

pub_date

2019-05-17 00:00:00

pages

47

issue

1

issn

1758-9193

pii

10.1186/s13195-019-0496-x

journal_volume

11

pub_type

杂志文章
  • Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

    abstract:BACKGROUND:Development of new treatments for Alzheimer's disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-016-0170-5

    authors: Podhorna J,Krahnke T,Shear M,Harrison JE,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期:2016-02-12 00:00:00

  • Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome.

    abstract::The long-term consequences of repetitive head impacts have been described since the early 20th century. Terms such as punch drunk and dementia pugilistica were first used to describe the clinical syndromes experienced by boxers. A more generic designation, chronic traumatic encephalopathy (CTE), has been employed sinc...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-014-0068-z

    authors: Montenigro PH,Baugh CM,Daneshvar DH,Mez J,Budson AE,Au R,Katz DI,Cantu RC,Stern RA

    更新日期:2014-09-24 00:00:00

  • Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease.

    abstract:BACKGROUND:Neuroinflammation has gained increasing attention as a potential contributing factor in Alzheimer's disease (AD) pathology. A clinical cerebrospinal fluid biomarker capable of monitoring this process during the course of the disease has yet to emerge, chiefly owing to contradictory research findings. In this...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0353-3

    authors: Brosseron F,Traschütz A,Widmann CN,Kummer MP,Tacik P,Santarelli F,Jessen F,Heneka MT

    更新日期:2018-02-26 00:00:00

  • Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.

    abstract:BACKGROUND:The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-making for multicentre research studies and clinical trials. In this study, we aimed at deriving reference Ce...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0478-z

    authors: Salvadó G,Molinuevo JL,Brugulat-Serrat A,Falcon C,Grau-Rivera O,Suárez-Calvet M,Pavia J,Niñerola-Baizán A,Perissinotti A,Lomeña F,Minguillon C,Fauria K,Zetterberg H,Blennow K,Gispert JD,Alzheimer’s Disease Neuroimaging Init

    更新日期:2019-03-21 00:00:00

  • Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative.

    abstract:BACKGROUND:Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Multiple studies show that patients with Alzheimer's disease (AD) exhibit thinning in several retinal layers compared to age-matched controls. Subjective cognitive ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00602-9

    authors: Marquié M,Valero S,Castilla-Marti M,Martínez J,Rodríguez-Gómez O,Sanabria Á,Tartari JP,Monté-Rubio GC,Sotolongo-Grau O,Alegret M,Pérez-Cordón A,Roberto N,de Rojas I,Moreno-Grau S,Montrreal L,Hernández I,Rosende-Roca M,M

    更新日期:2020-03-31 00:00:00

  • Functional connectivity in cognitive control networks mitigates the impact of white matter lesions in the elderly.

    abstract:BACKGROUND:Cerebrovascular pathology, quantified by white matter lesions (WML), is known to affect cognition in aging, and is associated with an increased risk of dementia. The present study aimed to investigate whether higher functional connectivity in cognitive control networks mitigates the detrimental effect of WML...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0434-3

    authors: Benson G,Hildebrandt A,Lange C,Schwarz C,Köbe T,Sommer W,Flöel A,Wirth M

    更新日期:2018-10-27 00:00:00

  • The effects of different familial Alzheimer's disease mutations on APP processing in vivo.

    abstract:BACKGROUND:Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer's disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a model for the sporadic form of AD. In FAD the diagnosis of AD is reliable and presymptomatic individu...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0234-1

    authors: Thordardottir S,Kinhult Ståhlbom A,Almkvist O,Thonberg H,Eriksdotter M,Zetterberg H,Blennow K,Graff C

    更新日期:2017-02-16 00:00:00

  • Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea.

    abstract:BACKGROUND:Subjective cognitive decline (SCD) is a potential risk factor for dementia. We aimed to investigate the association between SCD and subsequent dementia in a nationwide population-based cohort in South Korea. METHODS:This cohort included 579,710 66-year-old adults who were followed for a total of 3,870,293 p...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00618-1

    authors: Lee YC,Kang JM,Lee H,Kim K,Kim S,Yu TY,Lee EM,Kim CT,Kim DK,Lewis M,Won HH,Jessen F,Myung W

    更新日期:2020-05-06 00:00:00

  • Biomarkers in biological fluids for dementia with Lewy bodies.

    abstract::Dementia with Lewy bodies (DLB) has become the second most common neurodegenerative dementia due to demographic ageing. Differential diagnosis is still troublesome especially in early stages of the disease, since there is a great clinical and neuropathological overlap primarily with Alzheimer's disease and Parkinson's...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-014-0072-3

    authors: Schade S,Mollenhauer B

    更新日期:2014-10-16 00:00:00

  • Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?

    abstract:BACKGROUND:Alzheimer's disease (AD) pathophysiology is mostly (>95%) not inherited in a Mendelian fashion. Such sporadic AD (sAD) forms do not exhibit familial aggregation and are characterized by complex genetic inheritance. Growing evidence indicates that multiple genes contribute to sAD-characteristic endophenotypes...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt165

    authors: Hampel H,Lista S

    更新日期:2013-03-18 00:00:00

  • Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery.

    abstract::The Alzheimer's Drug Discovery Foundation's 13th International Conference on Alzheimer's Drug Discovery was held on 10-11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alzheimer's Drug Discovery Foundation-funded programs, ranging from novel biomarkers to accelerate clinical devel...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt159

    authors: Lane RF,Dacks PA,Shineman DW,Fillit HM

    更新日期:2013-02-04 00:00:00

  • Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).

    abstract:BACKGROUND:The pathophysiology of neurodegeneration is complex. Its diagnosis requires an early identification of sequential changes in several hallmarks in the brains of affected subjects. The presence of brain pathology can be visualized in the cerebrospinal fluid (CSF) by protein profiling. It is clear that the fiel...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0265-7

    authors: Vanderstichele H,Demeyer L,Janelidze S,Coart E,Stoops E,Mauroo K,Herbst V,François C,Hansson O

    更新日期:2017-06-06 00:00:00

  • Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.

    abstract:BACKGROUND:Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by neuropathologic changes involving beta-amyloid (Aβ), tau, neuronal loss, and other associated biological events. While levels of cerebrospinal fluid (CSF) Aβ and tau peptides have enhanced the antemortem detection of AD-specifi...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13195-018-0426-3

    authors: Gangishetti U,Christina Howell J,Perrin RJ,Louneva N,Watts KD,Kollhoff A,Grossman M,Wolk DA,Shaw LM,Morris JC,Trojanowski JQ,Fagan AM,Arnold SE,Hu WT

    更新日期:2018-09-25 00:00:00

  • In vivo quantification of neurofibrillary tangles with [18F]MK-6240.

    abstract:BACKGROUND:Imaging agents capable of quantifying the brain's tau aggregates will allow a more precise staging of Alzheimer's disease (AD). The aim of the present study was to examine the in vitro properties as well as the in vivo kinetics, using gold standard methods, of the novel positron emission tomography (PET) tau...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0402-y

    authors: Pascoal TA,Shin M,Kang MS,Chamoun M,Chartrand D,Mathotaarachchi S,Bennacef I,Therriault J,Ng KP,Hopewell R,Bouhachi R,Hsiao HH,Benedet AL,Soucy JP,Massarweh G,Gauthier S,Rosa-Neto P

    更新日期:2018-07-31 00:00:00

  • Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design.

    abstract::Recent trials of statins produced no benefit for subjects with Alzheimer's disease. These negative studies add to a growing list of negative clinical trials. These data point to a need for reevaluating the pathophysiology of late-onset Alzheimer's disease. Late-onset Alzheimer's disease might result from the cumulativ...

    journal_title:Alzheimer's research & therapy

    pub_type: 社论

    doi:10.1186/alzrt101

    authors: Wolozin B

    更新日期:2012-01-16 00:00:00

  • Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?

    abstract::Symptomatic treatments for Alzheimer's disease should retain a place in the advanced stages of disease since their actions on these symptoms, even if not modifying the course of disease, are critical for improving patients' comfort and reducing the burden felt by caregivers, especially those facing behavioral disorder...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt228

    authors: Ousset PJ,Delrieu J,Vellas B

    更新日期:2013-12-11 00:00:00

  • Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.

    abstract:INTRODUCTION:Peripheral biomarkers to diagnose Alzheimer's disease (AD) have not been established. Given parallels between neuron and platelet biology, we hypothesized platelet membrane-associated protein changes may differentiate patients clinically defined with probable AD from noncognitive impaired controls. METHOD...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt186

    authors: Donovan LE,Dammer EB,Duong DM,Hanfelt JJ,Levey AI,Seyfried NT,Lah JJ

    更新日期:2013-06-13 00:00:00

  • Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.

    abstract:BACKGROUND:Kallikrein 6 (KLK6) is known to be an age-related protease expressed at high levels in the central nervous system. It was previously shown to be involved in proteolysis of extracellular proteins implicated in neurodegenerative diseases such as Alzheimer's disease (AD), prompting validation of KLK6 as a poten...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0336-4

    authors: Patra K,Soosaipillai A,Sando SB,Lauridsen C,Berge G,Møller I,Grøntvedt GR,Bråthen G,Begcevic I,Moussaud S,Minthon L,Hansson O,Diamandis EP,White LR,Nielsen HM

    更新日期:2018-01-29 00:00:00

  • Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria.

    abstract:BACKGROUND:[18F]FDG-PET hypometabolism patterns are indicative of different neurodegenerative conditions, even from the earliest disease phase. This makes [18F]FDG-PET a valuable tool in the diagnostic workup of neurodegenerative diseases. The utility of [18F]FDG-PET in dementia with Lewy bodies (DLB) needs further val...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0473-4

    authors: Caminiti SP,Sala A,Iaccarino L,Beretta L,Pilotto A,Gianolli L,Iannaccone S,Magnani G,Padovani A,Ferini-Strambi L,Perani D

    更新日期:2019-02-23 00:00:00

  • Structured relearning of activities of daily living in dementia: the randomized controlled REDALI-DEM trial on errorless learning.

    abstract:BACKGROUND:Errorless learning (EL) is a method for optimizing learning, which uses feed-forward instructions in order to prevent people from making mistakes during the learning process. The majority of previous studies on EL taught patients with dementia artificial tasks of little or no relevance for their daily lives....

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/s13195-017-0247-9

    authors: Voigt-Radloff S,de Werd MM,Leonhart R,Boelen DH,Olde Rikkert MG,Fliessbach K,Klöppel S,Heimbach B,Fellgiebel A,Dodel R,Eschweiler GW,Hausner L,Kessels RP,Hüll M

    更新日期:2017-03-23 00:00:00

  • Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.

    abstract:BACKGROUND:Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. METHODS:Here we describe the first clinical study with BAN2401. Safety and tolerability were...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1186/s13195-016-0181-2

    authors: Logovinsky V,Satlin A,Lai R,Swanson C,Kaplow J,Osswald G,Basun H,Lannfelt L

    更新日期:2016-04-06 00:00:00

  • Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review.

    abstract:BACKGROUND:A growing number of pharmacological and nonpharmacological trials have been performed to test the efficacy of approved or experimental treatments in Alzheimer disease (AD) and mild cognitive impairment (MCI). In this context, functional magnetic resonance imaging (fMRI) may be a good candidate to detect brai...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-018-0347-1

    authors: Canu E,Sarasso E,Filippi M,Agosta F

    更新日期:2018-02-20 00:00:00

  • Alzheimer's disease drug-development pipeline: few candidates, frequent failures.

    abstract:INTRODUCTION:Alzheimer's disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. METHODS:We examined Clinical...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt269

    authors: Cummings JL,Morstorf T,Zhong K

    更新日期:2014-07-03 00:00:00

  • Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease.

    abstract:INTRODUCTION:There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease (AD) assessed by repeated measures on serial tests of cognition and function. METHODS:Six hundre...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt7

    authors: Rountree SD,Chan W,Pavlik VN,Darby EJ,Siddiqui S,Doody RS

    更新日期:2009-10-21 00:00:00

  • The Third French Alzheimer Plan: analysis of the influence of a national public health initiative on scientific research productivity and impact.

    abstract:INTRODUCTION:The Third National Alzheimer Plan (2008-2012) was a major public health initiative in France that included €200 million of funding for research in Alzheimer disease and related disorders (AD). The aim of this study was to document trends in French academic output in AD following the implementation of the p...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0144-z

    authors: Haeffner-Cavaillon N,Devos P,Ledoux S,Ménard J

    更新日期:2015-09-26 00:00:00

  • Changes in the neurochemistry of athletes with repetitive brain trauma: preliminary results using localized correlated spectroscopy.

    abstract:INTRODUCTION:The goal was to identify which neurochemicals differ in professional athletes with repetitive brain trauma (RBT) when compared to healthy controls using a relatively new technology, in vivo Localized COrrelated SpectroscopY (L-COSY). METHODS:To achieve this, L-COSY was used to examine five former professi...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0094-5

    authors: Lin AP,Ramadan S,Stern RA,Box HC,Nowinski CJ,Ross BD,Mountford CE

    更新日期:2015-03-15 00:00:00

  • A language-based sum score for the course and therapeutic intervention in primary progressive aphasia.

    abstract:BACKGROUND:With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential therapeutic effects. So far, volumetric brain changes have been proposed as clinical endpoints in the lit...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0345-3

    authors: Semler E,Anderl-Straub S,Uttner I,Diehl-Schmid J,Danek A,Einsiedler B,Fassbender K,Fliessbach K,Huppertz HJ,Jahn H,Kornhuber J,Landwehrmeyer B,Lauer M,Muche R,Prudlo J,Schneider A,Schroeter ML,Ludolph AC,Otto M,FTLD

    更新日期:2018-04-25 00:00:00

  • Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

    abstract::In May 2012, the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia brought together in Montreal experts from around Canada to update Canadian recommendations for the diagnosis and management of patients with neurodegenerative conditions associated with deterioration of cognition. Multiple...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt199

    authors: Soucy JP,Bartha R,Bocti C,Borrie M,Burhan AM,Laforce R,Rosa-Neto P

    更新日期:2013-07-08 00:00:00

  • A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

    abstract:BACKGROUND:In Alzheimer's disease, beta-amyloid peptides in the brain aggregate into toxic oligomers and plaques, a process which is associated with neuronal degeneration, memory loss, and cognitive decline. One therapeutic strategy is to decrease the production of potentially toxic beta-amyloid species by the use of i...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章

    doi:10.1186/s13195-016-0178-x

    authors: Hölttä M,Dean RA,Siemers E,Mawuenyega KG,Sigurdson W,May PC,Holtzman DM,Portelius E,Zetterberg H,Bateman RJ,Blennow K,Gobom J

    更新日期:2016-03-07 00:00:00

  • HHV-6A infection induces amyloid-beta expression and activation of microglial cells.

    abstract:BACKGROUND:The control of viral infections in the brain involves the activation of microglial cells, the macrophages of the brain that are constantly surveying the central nervous system, and the production of amyloid-beta (Aβ) as an anti-microbial molecule. Recent findings suggest a possible implication of HHV-6A in A...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0552-6

    authors: Bortolotti D,Gentili V,Rotola A,Caselli E,Rizzo R

    更新日期:2019-12-12 00:00:00